Surface Proteomics for ADCs and CAR-T Design
Why Cell Therapy Target Selection Is So Difficult Antibody-drug conjugates (ADCs) and CAR-T therapies have reshaped modern oncology, but their success still depends on one deceptively simple question: are we targeting the right protein? In practice, answering this is...
Advancing the Frontier of Translational Proteomic Insights
Transcript featuring Gary Patti (Panome Bio) and Dipender Gill (Sequoia Genetics) DIPENDER So Gary, great to get a chance to talk again. I know we’ve had numerous really stimulating conversations about proteomics, genetics, the intersection of science, and how...
Surface Proteomics for Smarter Drug Target Discovery
Drug development is expensive, slow, and highly unpredictable. Despite major advances in genomics and precision medicine, nearly 90% of drug candidates still fail (Doi: 10.1016/j.apsb.2022.02.002) during clinical development, often because the selected target was not...